

Selected References

1. Bueid A, et al. Azole antifungal resistance in *Aspergillus fumigatus*: 2008 and 2009. *J Antimicrob Chemother.* 2010;65:2116-8. Available at: <http://jac.oxfordjournals.org/content/65/10/2116.long>.
2. van der Linden JW, et al. Clinical implications of azole resistance in *Aspergillus fumigatus*, The Netherlands, 2007-2009. *Emerg Infect Dis.* 2011;17:1846-54. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311118/>.
3. van der Linden JWM, et al. Aspergillosis due to voriconazole highly resistant *Aspergillus fumigatus* and recovery of genetically related resistant isolates from domiciles. *Clin Infect Dis.* 2013;57:513-20. Abstract available at: <http://www.ncbi.nlm.nih.gov/pubmed/23667263>.
4. Cleveland AA, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. *Clin Infect Dis.* 2012;55:1352-60. Available at: <http://cid.oxfordjournals.org/content/55/10/1352.long>.
5. Lockhart SR, et al. Species identification and antifungal susceptibility testing of *Candida* bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. *J Clin Microbiol.* 2012;50:3435-42. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486211/>.
6. Pfaller MA, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of *Candida* Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. *J Clin Microbiol.* 2010;48:1366-77. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849609/>.
7. Alexander BD, et al. Increasing echinocandin resistance in *Candida glabrata*: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. *Clin Infect Dis.* 2013;56:1724-32. Available at: <http://cid.oxfordjournals.org/content/56/12/1724.long>.
8. Shields RK, et al. Caspofungin MICs correlate with treatment outcomes among patients with *Candida glabrata* invasive candidiasis and prior echinocandin exposure. *Antimicrob Agent Chemother.* 2013; 57: 3528-35. Abstract available at: <http://www.ncbi.nlm.nih.gov/pubmed/23669387>.
9. Husain S, et al. Performance characteristics of the platelia *Aspergillus* enzyme immunoassay for detection of *Aspergillus* galactomannan antigen in bronchoalveolar lavage fluid. *Clin Vaccine Immunol.* 2008;15:1760-3. Available at: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2593174/>.
10. Mengoli C, et al. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. *Lancet Infect Dis.* 2009;9:89-86. Abstract available at: <http://www.ncbi.nlm.nih.gov/pubmed/19179225>.
11. Morrissey CO, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. *Lancet Infect Dis.* 2013;13:519-28. Abstract available at: <http://www.ncbi.nlm.nih.gov/pubmed/23639612>.
12. Trifilio S, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. *Cancer.* 2007;109:1532-5. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/cncr.22568/pdf>.
13. Millon L, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. 2013;56:e95-101. Available at: <http://cid.oxfordjournals.org/content/56/10/e95.long>.

